Drug Profile
Research programme: adenoviral gene therapy - Shanghai Sunway Biotech
Alternative Names: H-102; H100 seriesLatest Information Update: 28 Aug 2019
Price :
$50
*
At a glance
- Originator Shanghai Sunway Biotech
- Class Antineoplastics; Gene therapies
- Mechanism of Action P53 gene modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Aug 2019 No recent reports of development identified for preclinical development in Cancer in China (Intratumoural, Injection)
- 01 Jul 2015 Preclinical trials in Cancer in China (Intratumoural)